Ascendia

  MARKET NEWS

Vaxart Reports Positive Clinical Data Demonstrating its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses Than its First-Generation Technology
Nicoya Acquires Applied Photophysics, Expanding Biologics Characterization Capabilities for Faster Time-to-Clinic & Reduced Late-Stage Failures
CN Bio Introduces Cross-Species DILI Services to Enhance In Vitro to In Vivo Extrapolation During Preclinical Drug Development
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension
Adcendo ApS Announces First Patient Dosed in Phase 1/2 ADCElerate1 Trial of ADCE-D01

  EXPERT CONTENT & RESOURCES

Exploring New Potential Through 505(b)(2)

Exploring New Potential Through 505(b)(2)

When filing for a drug product approval via the 505(b)(2) regulatory pathway rather than a traditional development pathway, companies are afforded several advantages.

Ionizable Lipids in LNPs: A Selection Guide

Ionizable Lipids in LNPs: A Selection Guide

Finding the right ionizable lipid is critical for optimal formulations. This guide helps navigate the wide range of ionizable lipids for specific therapeutic needs. Explore lipids by target or cargo type.

Lyophilization Development: Quality by Design Approach

Lyophilization Development: Quality by Design Approach

Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……

  FEATURED EDITORIAL

  COMPANY PROFILE

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies that accelerate access to life-saving cell therapies. Cellares’ flagship technologies—the Cell Shuttle™, an automated manufacturing platform, and Cell Q™, an automated quality control system— will power a global network of Smart Factories that can produce up to 10x more therapies and reduce batch prices by up to 50% compared to conventional CDMOs. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story

WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story

Our client, a leading pharmaceutical company, came to us for a solution to a very specific problem. They needed a staked needle prefilled syringe (PFS) in a disposable auto-injector for their high-concentration monoclonal antibody product. These products are among the …

WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges

WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges

Veterinary medicines face unique challenges due to species diversity, physiology, and dosing needs. Animals can’t be instructed to take medicine, so palatability, safety, and bioavailability are key.

Gattefossé focuses on customers, veterinarians, pet owners, and animals themselves to help them …

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

The pharmaceutical industry has been acquainted with the promise of 3D printing for some time now, with many large pharma companies exploring the possibilities of the technology. However, 3D-printed pharmaceuticals have been largely relegated to niche markets and prototyping due …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 18 – Bioavailability
June 25 – Excipients